Blockades of CTLA-4 and PD-1 function at different times in the immune cascade and at different locations (Figure 1), leading to the hypothesis that these therapies may have an additive or synergistic effect in the treatment of cancer (10). This evidence concerns the gene CTLA4 and cancer.